Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
Synonyms: XLP, Duncan's disease, familial fatal Epstein-Barr virus infection, Purtilo's syndrome
This X-linked inherited disorder (thus affecting boys) resulting from a defective gene at Xq25 is characterised by a severe susceptibility to Epstein-Barr virus (EBV) infections.
Following exposure, 75% of patients develop a severe or fatal infectious mononucleosis. Survivors may go on to develop an acquired hypogammaglobulinaema, red cell aplasia, aplastic anaemia or lymphomatoid granulomatosis.[2, 3]
Patients present in childhood (mean age 3-5 years) with signs of EBV infection:
- Respiratory: pharyngitis, lymphoid granulomatosis of lung.
- Abdomen: hepatomegaly, fulminant hepatitis and liver failure, splenomegaly.
- Haematological: atypical mononucleosis (lymphocytosis); thrombocytopenia or bone marrow failure.
- CNS: meningitis or encephalitis, hepatic encephalopathy.
Bone marrow transplant is the definitive treatment.[4, 5] Transplantation of cord-blood stem cells from an HLA-identical sibling has also been successful.
There is research into the use of anti-CD20 rituximab (monoclonal antibody) in the acute phase of EBV infection which shows promise, and cytotoxic chemotherapy may also have a role.
Genetic testing can identify affected individuals and carriers, and antenatal diagnosis is possible.
Without transplant, 70% of patients will not survive beyond 10 years of age.
Further reading and references
Arkwright PD, Makin G, Will AM, et al; X linked lymphoproliferative disease in a United Kingdom family. Arch Dis Child. 1998 Jul79(1):52-5.
Seiter K et al; Lymphoproliferative Syndrome, X-linked, Medscape, Mar 2011
Purtilo DT, Sakamoto K, Barnabei V, et al; Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): update on studies of the registry. Am J Med. 1982 Jul73(1):49-56.
Pracher E, Panzer-Grumayer ER, Zoubek A, et al; Successful bone marrow transplantation in a boy with X-linked lymphoproliferative syndrome and acute severe infectious mononucleosis. Bone Marrow Transplant. 1994 May13(5):655-8.
Hoffmann T, Heilmann C, Madsen HO, et al; Matched unrelated allogeneic bone marrow transplantation for recurrent malignant lymphoma in a patient with X-linked lymphoproliferative disease (XLP). Bone Marrow Transplant. 1998 Sep22(6):603-4.
Vowels MR, Tang RL, Berdoukas V, et al; Brief report: correction of X-linked lymphoproliferative disease by transplantation of cord-blood stem cells. N Engl J Med. 1993 Nov 25329(22):1623-5.